Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

LPCN 1021 is an oral testosterone replacement product candidate that is under FDA review as a replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.


Phase 3 SOAR Trial

SOAR (Study Of Androgen Replacement) was a 52-week, multicenter, randomized, open-label, parallel-group, active-controlled Phase 3 study of LPCN 1021. Males 18 to 80 years old with a diagnosis of hypogonadism and confirmed low testosterone (< 300 ng/dl) were eligible for the study; a documented diagnosis of onset of hypogonadism prior to age 65 was required for patients older than 65 years. A total of 315 subjects were randomized across 40 study sites in 2:1 ratio, such that 210 were randomized to LPCN 1021 and 105 were randomized to Androgel 1.62% (active control for safety evaluation). LPCN 1021 subjects were started at 225 mg TU (equivalent to ~ 142 mg of T) twice daily (BID) and then titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum testosterone as measured during weeks 3 and 7.

The safety of LPCN 1021 was monitored over 52 weeks of treatment. Additional parameters assessed after 52 weeks of treatment included:

  • Change from baseline in safety laboratory parameters
  • Number of subjects with adverse events

Primary statistical analysis was conducted using the Efficacy Population Set ("EPS") and additional analysis was performed using the Full Analysis Set ("FAS") as defined below:

  • Primary Analysis: Efficacy Population Set (EPS, N = 151)
    • Subjects randomized into the study with at least one PK profile and no significant protocol deviations
    • Imputed missing data by Last Observation Carried Forward (LOCF)
  • Additional Analysis: Full Analysis Set (FAS, N = 193)
    • Subjects randomized into the study and had at least one post baseline efficacy variable response
    • Imputed missing data by Last Observation Carried Forward (LOCF)


  • Primary endpoint target ≥ 75% subjects should achieve Cavg within normal range (300 ng/dL to 1140 ng/dL) and lower bound of 95% CI ≥ 65%


FDA Targets

Efficacy Population


Number of subjects




% subjects with Cavg
within normal range




95 % CI lower bound






Mean (%CV)

Mean (%CV)

Cavg (ng/dL )


446 (38%)

478 (41%)

In the EPS analysis, 87% of the subjects on LPCN 1021 achieved testosterone Cavg within the normal range with lower bound CI of 82%. Results for the sensitivity analysis using the FAS were similar to results for the EPS.

Other highlights from the efficacy results include:

  • Mean Cavg was 446 ng/dL with coefficient of variance of 38%
  • Less than 13% of the subjects were outside the testosterone Cavg normal range at final dose
  • 85% of subjects arrived at final dose with no more than one titration
  • 52% of subjects were on final dose of 225 mg BID

Final dose distribution of subjects:

Dose (mg TU, BID)

% of Subjects


32 %

225 *

52 %


16 %

* Most subjects with final dose of 225 mg BID

SOAR trial titration outcomes


% of subjects

% subjects requiring  no more than one dose change
(either after week 3 or week 7)

89.2 %

% subjects requiring two dose changes
(both after week 3 and 7)

10.8 %

Most subjects (89%) achieved optimal LPCN 1021 dose with one or fewer titrations whereas 61% of subjects required 2 titrations with active control

Secondary Endpoints

  • Proportion of subjects achieving maximum serum total T concentrations (Cmax) in predefined Cmax range


FDA Threshold

Efficacy Population

Number of subjects 



Cmax < 1500 ng/dL

≥ 85 %


1800 ≤ Cmax ≤ 2500 ng/dL

≤ 5 %


Cmax > 2500 ng/dL



Safety Summary:

  • Adverse Events and Adverse Drug Reactions
    • AE's occurring in more than 5% of subjects with either treatment were upper respiratory tract infection (5.2% with LPCN 1021 and 5.8% with active control) and fatigue (2.4% with LPCN 1021 and 6.7% with active control).
    • No reported hepatic, cardiac, or drug-related serious adverse events occurred with either treatment.
    • None of the cardiac adverse events occurred in more than 1% of subjects in LPCN 1021 arm, and none were classified as severe.
    • ADRs, drug-related AEs, occurring in more than 2% of subjects with either treatment were headache (0.5% with LPCN 1021 and 3.9% with active control), acne (2.9% with LPCN 1021 and 2.9% with active control) and patient reported weight increase (2.4% with LPCN 1021 and 0% with active control).
    • Weight changes greater than 10% from baseline over 52 weeks occurred in 2.3% of subjects with LPCN 1021 and 3.8% of subjects with active control.
    • All observed adverse drug reactions were classified as mild or moderate in severity and no serious ADRs occurred during the 52-week treatment period.
  • Other Safety Parameters
    • No significant changes in mean systolic and diastolic blood pressure from baseline for either treatment.
    • Mean HDL level following LPCN 1021 decreased slightly from baseline but was not significantly different from the active control after 52 weeks.
    • Mean hematocrit, hemoglobin, platelet count, prothrombin time, and prostate specific antigen values were not significantly different from baseline.
    • Mean DHT levels increased from baseline following LPCN 1021 but were comparable to changes seen with active control.
  • Additional study results
    • LPCN 1021 achieved consistent intraday and interday performance

Phase 1 Food Effect Study

The food effect study was a single-center, open-label, randomized, single-dose, 4-period, 4-way crossover study. Subjects received the recommended starting dose of LPCN 1021, 225 mg as a single dose under fasted conditions and under the following fed conditions: approximately 30 minutes following an 800 to 1000 calorie meal with ~15% of calories from fat (i.e., low fat meal), ~30% calories from fat (i.e., standard fat meal), and ~50% calories from fat (i.e., high fat meal).

  • Bioequivalent levels of testosterone (Cmax and AUC) were achieved when LPCN 1021 was administered with various fat content of meal